Compare Johnson & Johnson (JNJ) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Invesco Preferred ETF — how do they compare? Johnson & Johnson trades at $260.64 (market cap $626.09B), while Invesco Preferred ETF trades at $10.68. The key difference: Johnson & Johnson pays a 2.06% dividend while Invesco Preferred ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | PGX | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | — |
52-Week High | $267.24 | $11.87 |
52-Week Low | $172.78 | $10.65 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
PGX trades at $10.675, up 0.23% today, with a bearish technical signal driven by moving averages. Key financial ratios are unavailable, but the company has declared dividends for H1-26 and H2-26. Recent news includes an article on preferred ETFs and a project sale by Prosper Gold Corp., though the latter may not directly relate to the US-listed entity.
The outlook is cautious due to bearish technicals and lack of fundamental data. Risks include potential misidentification with other entities and limited financial transparency. Investment appeal hinges on future earnings clarity and sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
